Salvia BioElectronics receives FDA Breakthrough Device Designation for innovative neurostimulation solution

Salvia BioElectronics B.V. (“Salvia”), a neurostimulation
platform company targeting chronic migraine, announced today that the U.S. Food and Drug Administration
(FDA) has granted Breakthrough Device Designation for its implantable neurostimulation system to address
chronic migraine.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...